Skip to main content
SpringerLink
Log in

Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy

  • Chapter
Book cover Micrometastasis

Part of the book series: Cancer Metastasis - Biology and Treatment ((CMBT,volume 5))

  • 232 Accesses

Abstract

The early and clinically occult spread of viable tumour cells to the organism is becoming acknowledged as a hallmark in cancer progression, since abundant clinical and experimental data suggest that these cells are precursors of subsequent distant relapse. Prospective clinical studies have shown that the presence of such immunostained cells in bone marrow is prognostically relevant with regard to relapse-free and overall survival of breast cancer patients. As current treatment strategies have not resulted in a substantial improvement of breast cancer mortality rates so far, it is noteworthy to consider the intriguing options of immunocytochemical screening of bone marrow aspirates for occult metastatic cells. Besides improved tumour staging, such screening offers opportunities for guiding patient stratification for adjuvant therapy trials, monitoring response to adjuvant therapies, which, at present, can only be assessed retrospectively after an extended period of clinical follow-up, or for specifically targeting tumour-biological therapies against disseminated tumour cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pantel K, Cote RJ, Fodstad Ø. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91:1113–24.

    Article  PubMed  CAS  Google Scholar 

  2. Schlimok G, Funke I, Holzmann B, Göttlinger HG, Schmidt G, Häuser H et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA. 1987;84:8672–6.

    Article  PubMed  CAS  ADS  Google Scholar 

  3. Pantel K, Schlimok G, Angstwurm M, Weckermann C, Schmaus W, Gath H et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 1994;3:165–73.

    Article  PubMed  CAS  Google Scholar 

  4. Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CRM et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med. 2000;342:525–33.

    Article  PubMed  CAS  Google Scholar 

  5. Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC et al. Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Brit Med J. 1987;295:1093–6.

    Article  CAS  Google Scholar 

  6. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–55.

    Article  PubMed  CAS  Google Scholar 

  7. Braun S, Pantel K. Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat. 1998;52:201–16.

    Article  PubMed  CAS  Google Scholar 

  8. Pantel K, Schlimok G, Braun S, Kutter D, Schaller G, Funke I et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85:1419–24.

    Article  PubMed  CAS  Google Scholar 

  9. Slamon JD, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  PubMed  CAS  Google Scholar 

  10. Baselga J, Tripathy D, Mendelsohn J, Baughman, Benz CC, Dantis L et al. Phase II study of weekly intravenous recombinant humanized anti-p185 Her2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–44.

    PubMed  CAS  Google Scholar 

  11. Braun S, Rosenberg R, Thorban S, Harbeck N. Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer. Semin Surg Oncol. 2001;20:334–46.

    Article  PubMed  CAS  Google Scholar 

  12. Schwarz G. Cytomorphology and cell yield in a new cytocentrifugal technique allowing the collection of the cell-free supernatant. Lab Med. 1991;15:45–50.

    Google Scholar 

  13. Dearnaley D, Ormerod M, Sloane J. Micrometastases in breast cancer: long-term follow-up of the first patient cohort. Eur J Cancer. 1991;27:236–9.

    Article  PubMed  CAS  Google Scholar 

  14. Dearnaley D, Sloane J, Ormerod M, Steele K, Coombes R, Clink H et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Brit J Cancer. 1983;44:85–90.

    Article  Google Scholar 

  15. Redding WH, Coombes RC, Monagham P, Clink HMD, Imrie SF, Dearnaley DP et al. Detection of micrometastases in patients with primary breast cancer. Lancet. 1983;2:1271–4.

    PubMed  CAS  Google Scholar 

  16. Funke I, Schraut W. Meta-analysis of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol. 1998;16:557–66.

    PubMed  CAS  Google Scholar 

  17. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol. 2001;19:3669–74.

    PubMed  CAS  Google Scholar 

  18. Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CRM, Schindlbeck C et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol. 2001;19:1468–75

    PubMed  CAS  Google Scholar 

  19. Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol. 2001;19:960–71.

    PubMed  CAS  Google Scholar 

  20. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up. Lancet. 1999;354:197–202.

    Article  PubMed  CAS  Google Scholar 

  21. Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat. 1998;49:27–33.

    Article  PubMed  CAS  Google Scholar 

  22. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652–64.

    Article  PubMed  CAS  Google Scholar 

  23. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Brit J Cancer. 1994;69:566–71.

    Article  PubMed  CAS  Google Scholar 

  24. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991;9:1749–56.

    PubMed  CAS  Google Scholar 

  25. Untch M, Kahlert S, Funke I, Boettcher B, Konecny G, Nestle-Kraemling C et al. Detection of cytokeratin 18-positive cells in bone marrow of breast cancer patients: no prediction of bad outcome. Proc Amer Soc Clin Oncol. 1999;18:639a (abstr #2472).

    Google Scholar 

  26. Molino A, Pelosi G, Turazza M, Sperotto L, Bonetti A, Nortilli R et al. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features. Breast Cancer Res Treat. 1997;42:23–30.

    Article  PubMed  CAS  Google Scholar 

  27. Funke I, Fries S, Rolle M, Heiss MM, Untch M, Bohmert H et al. Comparative analyses of bone marrow micrometastases in breast and gastric cancer. Int J Cancer. 1996;65:755–61.

    Article  PubMed  CAS  Google Scholar 

  28. Courtemanche DJ, Worth AJ, Coupland RW, Rowell JL, MacFarlane JK. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer. Can J Surg. 1991;34:21–6.

    PubMed  CAS  Google Scholar 

  29. Singletary SE, Larry L, Trucker SL, Spitzer G. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients. J Surg Oncol. 1991;47:32–6.

    Article  PubMed  CAS  Google Scholar 

  30. Mathieu MC, Friedman S, Bosq J, Caillou B, Spielmann M, Travagli JP et al. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat. 1990;15:21–6.

    Article  PubMed  CAS  Google Scholar 

  31. Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer. 1990;26:865–7.

    Article  PubMed  CAS  Google Scholar 

  32. Porro G, Menard S, Tagliabue E, Orefice S, Salvadori B, Squicciarini P et al. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer. 1988;61:2407–11.

    Article  PubMed  CAS  Google Scholar 

  33. Braun S, Müller M, Hepp F, Schlimok G, Riethmüller G, Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1998;90:1099–100.

    Article  PubMed  CAS  Google Scholar 

  34. Datta YH, Adams PT, Drobyski WR. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol. 1994;12:475–82.

    PubMed  CAS  Google Scholar 

  35. Fields KK, Elfenbein GJ, Trudeau WL, Perlinss JB, Jansen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol. 1996;14:1868–76.

    PubMed  CAS  Google Scholar 

  36. Vannucchi AM, Bosi A, Glinz S, Pacini P, Linari S, Saccardi R et al. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. Brit J Haematol. 1998;103(3):610–7.

    Article  CAS  Google Scholar 

  37. Slade MJ, Smith BM, Sinnett HD, Cross NCP, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol. 1999;17:870–9.

    PubMed  CAS  Google Scholar 

  38. Mapara MY, Körner IJ, Hildebrandt M, Bargou R, Krahl D, Reichardt P et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood. 1997;89:337–44.

    PubMed  CAS  Google Scholar 

  39. Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol. 1999;17:2015–19.

    PubMed  CAS  Google Scholar 

  40. Bettelheim R, Price KN, Gelber RD, Davis BW, Castiglione M, Neville AM. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet. 1990;335:1565–8.

    Google Scholar 

  41. De Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow up. Brit J Cancer. 1992;66:523–7.

    Article  PubMed  Google Scholar 

  42. Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma. Br J Cancer. 1986;54:631–6.

    Article  PubMed  CAS  Google Scholar 

  43. Nasser IA, Lee AKC, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in ‘node-negative’ breast carcinoma. Hum Pathol. 1993;24:950–7.

    Article  PubMed  CAS  Google Scholar 

  44. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer. 1996;73:88–95.

    Article  PubMed  CAS  Google Scholar 

  45. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet. 1999;354:896–900.

    Article  PubMed  CAS  Google Scholar 

  46. Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S et al. The detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer. 1994;74:1595–600.

    Article  PubMed  CAS  Google Scholar 

  47. Schönfeld A, Luqmani Y, Sinnett HD, Shousha S, Coombes RC. Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. Brit J Cancer. 1996;74:1639–42.

    Article  Google Scholar 

  48. Ridell B, Landys K. Incidence and histopathology of metastases of mammary carcinoma in biopsies from the posterior iliac creast. Cancer. 1979;44:1782–8.

    Article  PubMed  CAS  Google Scholar 

  49. Fisher B, Fisher ER, Guzman C, Copeland CE, Caceres E. The dissemination of subcutaneously inoculated tumor cell suspensions. Arch Surg. 1968;98:347–51.

    Google Scholar 

  50. Braun S, Hepp F, Sommer HL, Pantel K. Tumor antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer (Pred Oncol). 1999;84:1–5.

    Article  CAS  Google Scholar 

  51. Pantel K, Aignherr C, Köllermann J, Caprano J, Riethmüller G, Köllermann MW. Immunocytochemical detection of isolated tumor cells in bone marrow of patients with untreated stage C prostatic cancer. Eur J Cancer. 1995;31A: 1627–32.

    Article  PubMed  CAS  Google Scholar 

  52. Riesenberg R, Oberneder R, Kriegmair M, Epp M, Bitzer U, Hofstetter A et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumor cells. Histochem. 1993;99:61–6.

    Article  CAS  Google Scholar 

  53. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 1991;51:4712–15.

    PubMed  CAS  Google Scholar 

  54. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC et al. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer. J Natl Cancer Inst. 1997;89:1044–9.

    Article  PubMed  CAS  Google Scholar 

  55. Maehara Y, Hasuda S, Abe T, Oki E, Kakeji Y, Ohno S et al. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res. 1998;4:2129–34.

    PubMed  CAS  Google Scholar 

  56. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet. 1995;346:1334–5.

    Article  PubMed  CAS  Google Scholar 

  57. Choy A, McCulloch P. Induction of tumor cell shedding into effluent venous blood during breast cancer surgery. Brit J Cancer. 1996;73:79–82.

    Article  PubMed  CAS  Google Scholar 

  58. Ménard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue E et al. Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with tumor prognostic features. Brit J Cancer. 1994;69:1126–9.

    Article  PubMed  Google Scholar 

  59. Martignone S, Ménard S, Bufalino R, Cascinelli N, Pellegrini R, Tagliabue E et al. Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst. 1993;85:398–402.

    Article  PubMed  CAS  Google Scholar 

  60. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710–15.

    PubMed  CAS  Google Scholar 

  61. Freeman JW, Busch RK, Gyorkey F, Gyorkey P, Ross BE, Busch H. Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. Cancer Res. 1988;48:1244–51.

    PubMed  CAS  Google Scholar 

  62. Fidler IJ, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst. 1990;82:166–8.

    Article  PubMed  CAS  Google Scholar 

  63. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327–36.

    Article  PubMed  CAS  Google Scholar 

  64. Price JE, Aukerman SL, Ananthaswamy N, McIntyre BW, Schackert G, Fidler IJ. Metastatic potential of cloned murine melanoma cells transfected with activated c-Ha-ras. Cancer Res. 1989;49:4274–81.

    PubMed  CAS  Google Scholar 

  65. Pantel K, Schmaus W, Schlimok G, Riethmüller G. p53 immunostaining of megakaryocytes is preferentially observed in patients with epithelial malignancies. Blood. 1993;82:610a (abstract).

    Google Scholar 

  66. Schlimok G, Riethmüller G. Detection, characterization and tumorigenicity of tumor cells in human bone marrow. Semin Cancer Biol. 1990;1:207–15.

    PubMed  CAS  Google Scholar 

  67. Allgayer H, Heiss MM, Riesenberg R, Gruetzner KU, Tarabichi A, Babic R et al. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res. 1997;57:1394–9.

    PubMed  CAS  Google Scholar 

  68. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335:675–9.

    Article  PubMed  CAS  Google Scholar 

  69. Hall PA, Ray A, Lemoine NR, Midley CA, Krausz T, Lane DP. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet. 1991;338:531.

    Article  Google Scholar 

  70. Slamon JD, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science. 1989;244:707–12.

    Article  PubMed  CAS  ADS  Google Scholar 

  71. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Brit J Cancer. 1993;67(3):625–9.

    Article  PubMed  CAS  Google Scholar 

  72. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48(5):1238–43.

    PubMed  CAS  Google Scholar 

  73. Tiwari RK, Borgen PI, Wong GY, Cordon CC, Osborne MP. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 1992;12:419–25.

    PubMed  CAS  Google Scholar 

  74. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. 1987;1:423–30.

    PubMed  CAS  Google Scholar 

  75. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erb-B-2 onco-protein in human breast carcinomas: immunhistochemical assessment correlates with gene amplification. Lancet. 1987;2:69–72.

    Article  PubMed  CAS  Google Scholar 

  76. Braun S, Heumos I, Schlimok G, Schaller G, Riethdorf L, Riethmüller G et al. ErbB2 over-expression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I–III breast cancer patients. Cancer Res. 2001;61:1890–5.

    PubMed  CAS  Google Scholar 

  77. Taylor-Papadimitriou J. Oncogene signalling epithelial polarity and metastatic phenotype. In: The Lancet Conference, 1994; Brugge, Belgium; 1994, p. 7.

    Google Scholar 

  78. Hoffman M. New clue found to oncogene’s role in breast cancer. Science. 1992; 256:1129.

    Article  PubMed  CAS  ADS  Google Scholar 

  79. Lupu R, Colomer R, Kannan B, Lippman ME. Characterization of a growth factor that binds exclusively to the erbB2 receptor and induces cellular responses. Proc Natl Acad Sci USA. 1992;89:2287–91.

    Article  PubMed  CAS  ADS  Google Scholar 

  80. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kD glycoprotein that induces differentiation of mammary tumor cells. Cell. 1992;69:205–16.

    Article  PubMed  CAS  Google Scholar 

  81. Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G et al. Isolation of blood-borne epithelium derived c-erb-B2 oncoprotein-positive clustered cells from peripheral blood of breast cancer patients. Int J Cancer. 1998;76:824–8.

    Article  PubMed  CAS  Google Scholar 

  82. Riethmüller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr Opin Immunol. 1992;4:647–55.

    Article  PubMed  Google Scholar 

  83. Hämmerling G, Maschek V, Sturmhöfel K, Momburg F. Regulation and functional role of MHC expression on tumors. In: Melchers F, editor. Prog. Immunol. Berlin: Springer; 1989, p. 1071–8.

    Google Scholar 

  84. Behrens J, Frixen U, Schipper J, Weidner M, Birchmeier W. Cell adhesion in invasion and metastasis. Semin Cell Biol. 1992;3:169–78.

    Article  PubMed  CAS  Google Scholar 

  85. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochem Biophys Acta. 1989;989:65–84.

    PubMed  CAS  Google Scholar 

  86. Schwarz MA, Owaribe K, Kartenbeck J, Franke WW. Desmosomes and hemidesmosomes: constitutive molecular components. Annu Rev Cell Biol. 1990;6:461–91.

    Article  PubMed  CAS  Google Scholar 

  87. Pfeifer M. Cancer, catenins, and cuticle pattern: a complex connection. Science. 1993;262:667.

    Google Scholar 

  88. Göttlinger HG, Funke I, Johnson JP, Gokel JM, Riethmüller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer. 1986;38:47–53.

    Article  PubMed  Google Scholar 

  89. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol. 1994;12:1497–515.

    PubMed  CAS  Google Scholar 

  90. Braun S, Hepp F, Kentenich CRM, Janni W, Pantel K, Riethmüller G et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res. 1999;5:3999–4004.

    PubMed  CAS  Google Scholar 

  91. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmüller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer. 1995;31A:1799–803.

    Article  PubMed  CAS  Google Scholar 

  92. Scholz D, Lubeck M, Loibner H. Biological activity in the human system of isotype variants of oligosaccharide Y-specific murine monoclonal antibodies. Cancer Immunol Immunother. 1991;33:153–7.

    Article  PubMed  CAS  Google Scholar 

  93. Kruger WH, Kroger N, Togel F, Renges H, Badbaran A, Hornung R et al. Disseminated breast cancer cells prior to and after high-dose therapy. J Hematother Stem Cell Res. 2001;10:681–9.

    Article  PubMed  CAS  Google Scholar 

  94. Hohaus S, Funk L, Martin S, Schlenk R, Abdallah A, Hahn U et al. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Br J Cancer. 1999;79:1500–7.

    Article  PubMed  CAS  Google Scholar 

  95. Hempel D, Müller P, Oruzio D, Ehnle S, Schlimok G. Adoptive immunotherapy with monoclonal antibody 17-1A to reduce minimal residual disease in breast cancer patients after high-dose chemotherapy. Blood. 1997;90 Suppl. 1:379B, abstract #4454.

    Google Scholar 

  96. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50:2741–51.

    Google Scholar 

  97. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol. 1997;9:717–22.

    Article  PubMed  CAS  Google Scholar 

  98. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmüller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA. 1999;96:4494–99.

    Article  PubMed  CAS  ADS  Google Scholar 

  99. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O et al. Combined transcriptome and genome analysis of singel micrometastatic cells. Nat Biotech. 2002;20:387–92.

    Article  CAS  Google Scholar 

  100. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson JP et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res. 1999;59:241–8.

    PubMed  CAS  Google Scholar 

  101. Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Hoechtlen-Vollmar W et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst. 1995;87:1162–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leopold-Franzens-Universität, Universitätsklinik für Frauenheilkunde, Anichstrasse 35, A-6020, Innsbruck, Austria

    Stephan Braun

  2. Institut für Tumorbiologie, Universitätsklinikum Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany

    Volkmar Müller & Klaus Pantel

  3. Klinik für Frauenheilkunde, Universitätsklinikum Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany

    Volkmar Müller

Authors
  1. Stephan Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Volkmar Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Klaus Pantel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Tumour Biology, University Hospital Hamburg-Eppendorf, Germany

    Klaus Pantel (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Kluwer Academic Publishers

About this chapter

Cite this chapter

Braun, S., Müller, V., Pantel, K. (2003). Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy. In: Pantel, K. (eds) Micrometastasis. Cancer Metastasis - Biology and Treatment, vol 5. Springer, Dordrecht. https://doi.org/10.1007/0-306-48355-6_3

Download citation

  • DOI: https://doi.org/10.1007/0-306-48355-6_3

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-1155-9

  • Online ISBN: 978-0-306-48355-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation